Last reviewed · How we verify

NCT00832884

IV Lacosamide: The Safety of Intravenous Lacosamide

Completed Phase 4 Last updated 21 September 2020
What this trial tests

Phase 4 trial testing Lacosamide in Epilepsy in 40 participants. Completed in 1 November 2012.

Timeline
1 March 2010
Primary endpoint
1 May 2012
1 November 2012

Quick facts

Lead sponsorLe Bonheur Children's Hospital
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment40
Start date1 March 2010
Primary completion1 May 2012
Estimated completion1 November 2012
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Le Bonheur Children's Hospital

Who can join

Adults 4 to 35, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

To evaluate the safety of IV Lacosamide in children with partial-onset epilepsy, ages 4-35 years old, inclusive, who are either unable to take oral medication or require intravenous administration of IV Lacosamide.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Use of lacosamide in children with refractory epilepsy.
    Buck ML, Goodkin HP. · · 2012 · cited 18× · PMID 23258963 · DOI 10.5863/1551-6776-17.3.211

Verify or expand the search:

Other trials of Lacosamide

Trials testing the same drug.

Other recruiting trials for Epilepsy

Currently open trials in the same condition.

Other Le Bonheur Children's Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00832884.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing